Neonc Technologies Holdings, Inc.

NASDAQ:NTHI

Biotechnology

Healthcare
$4.33 +2.94%

+$0.14 today

Market cap
$124.92M
Beta
0.29
P/E (TTM)
-3.0
EPS (TTM)
-$1.66
52W Low $3.20High $12.99

Volume 0.26M

Average 0.08M

Returns on capital

Neonc Technologies Holdings, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

355.0%

avg 355.0%

ROIC

519.7%

avg 519.7%

ROA

-2200.9%

avg -2200.9%

Analysis

ROIC is currently the strongest return metric at 519.7% versus its period average of 519.7%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Thomas C. Chen

Founder, Chief Medical Officer, Chief Scientific Officer & Vice ChairmanUSD 212K6129.52K0.15%

Keithly A. Garnett

Chief Financial OfficerUSD 179K51——

Josh Neman-Ebrahim

Chief Clinical OfficerUSD 165K48——

Amir Farrokh Heshmatpour

President, Chief Executive Officer, Executive Chairman & Secretary—59——

David Choi

Chief Accounting Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

30

$1.81M

Sells

0

$0.00

Net Transaction Value

+$1.81M

Net buying

Most Active

Heshmatpour Amir F

16 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 13, 26

Heshmatpour Amir F

Direct

Buy$150.5K
Nov 11, 26

Heshmatpour Amir F

Direct

Buy$40K
Nov 11, 26

Heshmatpour Amir F

Direct

Buy$44.9K
Nov 10, 26

CHEN THOMAS C

Indirect

Buy$10K
Nov 10, 26

Heshmatpour Amir F

Direct

Buy$209.6K
Nov 9, 26

Heshmatpour Amir F

Direct

Buy$38.6K
Nov 9, 26

CHEN THOMAS C

Indirect

Buy$10K
Nov 6, 26

Heshmatpour Amir F

Direct

Buy$135.5K
Nov 5, 26

Heshmatpour Amir F

Direct

Buy$95K
Sep 15, 26

GARNETT KEITHLY

Direct

Buy$16.8K

1–10 of 30

Summary

Insiders reported 30 buys worth $1.81M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.81M. Heshmatpour Amir F was the most active insider with 16 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+392.0% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Forward estimates point to Revenue at +392.0% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Neonc Technologies Holdings, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Competitors

Peer companies in the same sector

Health

No competitor data available.

Questions

Management questions

Common questions about NTHI's management, answered from reported figures.

Who manages NTHI?

Neonc Technologies Holdings, Inc. (NTHI) lists 5 active executives. The top listed executive is Josh Neman-Ebrahim, Chief Clinical Officer.

Are NTHI insiders buying or selling?

Recent insider activity shows net selling of $1.81M.